JOP20240103A1 - المركبات والطرق التي تستهدف الإنترلوكين-34 - Google Patents
المركبات والطرق التي تستهدف الإنترلوكين-34Info
- Publication number
- JOP20240103A1 JOP20240103A1 JOJO/P/2024/0103A JOP20240103A JOP20240103A1 JO P20240103 A1 JOP20240103 A1 JO P20240103A1 JO P20240103 A JOP20240103 A JO P20240103A JO P20240103 A1 JOP20240103 A1 JO P20240103A1
- Authority
- JO
- Jordan
- Prior art keywords
- roads
- vehicles
- diseases
- target interleukin
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273216P | 2021-10-29 | 2021-10-29 | |
| PCT/US2022/078776 WO2023076995A1 (en) | 2021-10-29 | 2022-10-27 | Compounds and methods targeting interleukin-34 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240103A1 true JOP20240103A1 (ar) | 2024-04-29 |
Family
ID=84367272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0103A JOP20240103A1 (ar) | 2021-10-29 | 2024-04-29 | المركبات والطرق التي تستهدف الإنترلوكين-34 |
Country Status (19)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101706789B1 (ko) | 2008-07-21 | 2017-02-14 | 프로비오드룩 아게 | 진단용 항체 검사법 |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| SI3339323T1 (sl) | 2010-08-12 | 2019-12-31 | Eli Lilly And Company | Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| EP3174895A1 (en) | 2014-07-28 | 2017-06-07 | Nogra Pharma Limited | Methods and compositions for diagnosing and treating inflammatory bowel disorders |
| ES2870983T3 (es) | 2014-12-19 | 2021-10-28 | Univ Nantes | Anticuerpos anti-IL-34 |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| HK1249016A1 (zh) | 2015-06-02 | 2018-10-26 | 豪夫迈‧罗氏有限公司 | 使用抗il-34抗体治疗神经疾病的组合物和方法 |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| JP6949102B2 (ja) | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
| TWI789644B (zh) | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| EP3758736B1 (en) | 2018-03-02 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Il-34 for use in a method of treating retinal inflammation and neurodegeneration |
| KR102905634B1 (ko) | 2019-05-31 | 2025-12-30 | 일라이 릴리 앤드 캄파니 | 인간 타우를 표적화하는 화합물 및 방법 |
| AR121898A1 (es) | 2020-04-30 | 2022-07-20 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
-
2022
- 2022-10-27 IL IL312380A patent/IL312380A/en unknown
- 2022-10-27 TW TW111140796A patent/TW202336034A/zh unknown
- 2022-10-27 MX MX2024005153A patent/MX2024005153A/es unknown
- 2022-10-27 US US18/050,227 patent/US11976114B2/en active Active
- 2022-10-27 EP EP22814582.7A patent/EP4423127A1/en active Pending
- 2022-10-27 CA CA3236555A patent/CA3236555A1/en active Pending
- 2022-10-27 AR ARP220102931A patent/AR127484A1/es unknown
- 2022-10-27 KR KR1020247017337A patent/KR20240099349A/ko active Pending
- 2022-10-27 CN CN202280086946.7A patent/CN118475610A/zh active Pending
- 2022-10-27 JP JP2022172479A patent/JP7622019B2/ja active Active
- 2022-10-27 CR CR20240170A patent/CR20240170A/es unknown
- 2022-10-27 WO PCT/US2022/078776 patent/WO2023076995A1/en not_active Ceased
- 2022-10-27 PE PE2024000938A patent/PE20241471A1/es unknown
- 2022-10-27 AU AU2022376940A patent/AU2022376940A1/en active Pending
-
2024
- 2024-04-05 US US18/628,082 patent/US20240309082A1/en active Pending
- 2024-04-17 JP JP2024066552A patent/JP2024091777A/ja active Pending
- 2024-04-26 CL CL2024001303A patent/CL2024001303A1/es unknown
- 2024-04-26 DO DO2024000076A patent/DOP2024000076A/es unknown
- 2024-04-26 CO CONC2024/0005417A patent/CO2024005417A2/es unknown
- 2024-04-29 EC ECSENADI202432906A patent/ECSP24032906A/es unknown
- 2024-04-29 JO JOJO/P/2024/0103A patent/JOP20240103A1/ar unknown
-
2025
- 2025-01-15 JP JP2025005276A patent/JP2025063187A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240099349A (ko) | 2024-06-28 |
| CR20240170A (es) | 2024-05-24 |
| JP2023067832A (ja) | 2023-05-16 |
| US20230279094A1 (en) | 2023-09-07 |
| WO2023076995A1 (en) | 2023-05-04 |
| EP4423127A1 (en) | 2024-09-04 |
| JP2025063187A (ja) | 2025-04-15 |
| CL2024001303A1 (es) | 2024-08-30 |
| IL312380A (en) | 2024-06-01 |
| CA3236555A1 (en) | 2023-05-04 |
| DOP2024000076A (es) | 2024-06-16 |
| CN118475610A (zh) | 2024-08-09 |
| TW202336034A (zh) | 2023-09-16 |
| CO2024005417A2 (es) | 2024-05-30 |
| US11976114B2 (en) | 2024-05-07 |
| JP7622019B2 (ja) | 2025-01-27 |
| ECSP24032906A (es) | 2024-05-31 |
| PE20241471A1 (es) | 2024-07-17 |
| MX2024005153A (es) | 2024-05-13 |
| JP2024091777A (ja) | 2024-07-05 |
| AR127484A1 (es) | 2024-01-31 |
| AU2022376940A1 (en) | 2024-05-02 |
| US20240309082A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220285A1 (ar) | مركبات وطرق تستهدف إنترلوكين-34 | |
| ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| CY1122265T1 (el) | Αντισωματα εναντι ταυ και χρησεις αυτων | |
| AU2003270643A1 (en) | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| EA202192888A1 (ru) | Соединения и способы нацеливания на тау человека | |
| PH12020551019A1 (en) | IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| PE20191614A1 (es) | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo | |
| JOP20250030A1 (ar) | متقارنات وبروتينات ربط مستقبل الترانسفيرين | |
| JOP20230036A1 (ar) | نواهض مستقبل أوريكسين بيروليدين سيكلوهيبتان | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| EA201992688A1 (ru) | Средства, пути применения и способы лечения | |
| MA53765B2 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| JOP20220255A1 (ar) | أجسام tau المضادة لـ phf المضاد واستخداماتها | |
| EP4696310A3 (en) | Methods and compositions for modulation of tau proteins | |
| CO2020014681A2 (es) | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
| MY206530A (en) | Methods for treating neurodegenerative disorders | |
| MX2022011199A (es) | Peptidos ciclicos. | |
| MX2024005153A (es) | Compuestos y metodos dirigidos a la interleucina-34. | |
| EA202092123A1 (ru) | Антитела против клаудина 18.2 и их применения |